Who Optimizes SG&A Costs Better? Sarepta Therapeutics, Inc. or Amphastar Pharmaceuticals, Inc.

SG&A Cost Management: Amphastar vs. Sarepta

__timestampAmphastar Pharmaceuticals, Inc.Sarepta Therapeutics, Inc.
Wednesday, January 1, 20144037300049315000
Thursday, January 1, 20154697400075043000
Friday, January 1, 20164729800083749000
Sunday, January 1, 201750918000122682000
Monday, January 1, 201858044000207761000
Tuesday, January 1, 201963109000284812000
Wednesday, January 1, 202065157000317875000
Friday, January 1, 202168920000282660000
Saturday, January 1, 202266592000451421000
Sunday, January 1, 202380393000481871000
Loading chart...

Unlocking the unknown

Optimizing SG&A Costs: A Tale of Two Biopharma Giants

In the competitive world of biopharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Over the past decade, Amphastar Pharmaceuticals, Inc. and Sarepta Therapeutics, Inc. have taken different paths in optimizing these costs. From 2014 to 2023, Amphastar's SG&A expenses grew by approximately 99%, while Sarepta's surged by an astounding 878%. Despite this, Amphastar maintained a more consistent growth pattern, with expenses increasing steadily each year. In contrast, Sarepta experienced a dramatic rise, particularly between 2018 and 2023, where costs more than doubled. This divergence highlights the strategic differences in cost management between the two companies. As investors and industry analysts look to the future, understanding these trends provides valuable insights into each company's operational efficiency and strategic priorities.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025